Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Change in Accured Expenses (2016 - 2026)

Tenax Therapeutics' Change in Accured Expenses history spans 8 years, with the latest figure at $172693.0 for Q4 2017.

  • On a quarterly basis, Change in Accured Expenses fell 85.92% to $172693.0 in Q4 2017 year-over-year; TTM through Dec 2017 was -$5.0 million, a 363.63% decrease, with the full-year FY2025 number at -$421000.0, down 180.5% from a year prior.
  • Change in Accured Expenses hit $172693.0 in Q4 2017 for Tenax Therapeutics, up from -$1.3 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for TENX hit a ceiling of $1.9 million in Q1 2016 and a floor of -$2.9 million in Q2 2017.
  • Historically, Change in Accured Expenses has averaged -$228311.3 across 5 years, with a median of -$108808.5 in 2013.
  • Biggest five-year swings in Change in Accured Expenses: crashed 1579.32% in 2014 and later soared 427.06% in 2016.
  • Tracing TENX's Change in Accured Expenses over 5 years: stood at $25654.0 in 2013, then skyrocketed by 206.35% to $78590.0 in 2014, then surged by 196.07% to $232684.0 in 2015, then soared by 427.06% to $1.2 million in 2016, then tumbled by 85.92% to $172693.0 in 2017.
  • Business Quant data shows Change in Accured Expenses for TENX at $172693.0 in Q4 2017, -$1.3 million in Q3 2017, and -$2.9 million in Q2 2017.